In terms of safety, both lebrikizumab and tralokinumab were well tolerated, with the except that they were linked to an increased risk of conjunctivitis compared to placebo treatment.<h4>Conclusion</h4>Antagonizing IL-13 with lebrikizumab and tralokinumab have demonstrated encouraging clinical efficacy against moderate-to-severe AD with excellent safety profile, albeit they did come with a higher risk of conjunctivitis than placebo treatment.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/prospero/, identifier ID=CRD42021254920. This evidence concerns the gene IL13 and conjunctivitis.